Moreover, we also found that the expression levels of EMX2OS and TLN2 were significantly reduced in ccRCC patients, and the expression levels of EMX2OS and TLN2 were significantly associated with anti‐PD1 immunotherapy and anti‐CTLA4 immunotherapy. This evidence concerns the gene EMX2OS and nonpapillary renal cell carcinoma.